Literature DB >> 9584665

New approaches to therapy of amyotrophic lateral sclerosis.

R G Miller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9584665      PMCID： PMC1304952     

Source DB:  PubMed          Journal:  West J Med        ISSN： 0093-0415


× No keyword cloud information.
  4 in total

1.  Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis.

Authors:  M E Gurney; F B Cutting; P Zhai; A Doble; C P Taylor; P K Andrus; E D Hall
Journal:  Ann Neurol       Date:  1996-02       Impact factor: 10.422

2.  Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group.

Authors:  R G Miller; D Moore; L A Young; C Armon; R J Barohn; M B Bromberg; W W Bryan; D F Gelinas; M C Mendoza; H E Neville; G J Parry; J H Petajan; J M Ravits; S P Ringel; M A Ross
Journal:  Neurology       Date:  1996-12       Impact factor: 9.910

3.  Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group.

Authors:  E C Lai; K J Felice; B W Festoff; M J Gawel; D F Gelinas; R Kratz; M F Murphy; H M Natter; F H Norris; S A Rudnicki
Journal:  Neurology       Date:  1997-12       Impact factor: 9.910

4.  Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II.

Authors:  L Lacomblez; G Bensimon; P N Leigh; P Guillet; V Meininger
Journal:  Lancet       Date:  1996-05-25       Impact factor: 79.321
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.